** daily **
** daily **
** weekly **
** weekly **
** monthly **
Cempra is a development-stage and clinical-stage pharmaceutical company focused on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections. Its program CEM-101 is developing in both oral and intravenous (IV), formulations initially for the treatment of community-acquired bacterial pneumonia (CABP). Its second program is Taksta, which is developing in the United States as an oral treatment for bacterial infections caused by Staphylococcus aureus (S. Aureus), including methicillin-resistant S. aureus (MRSA). As of January 30, 2012, the Company completed a Phase II clinical trial in, which the oral formulation of CEM-101 demonstrated comparable efficacy to the levofloxacin. As of January 30, 2012, its second program Taksta has completed a Phase II clinical trial in patients.
Address
Building Four Quadrangle Suite 100, 6340 Quadrangle Drive
CHAPEL HILL, NC 27517-8149
United States
CHAPEL HILL, NC 27517-8149
United States
Website
cempra.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | -92.23% | - |
| Operating margin | -84.08% | - |
| EBITD margin | - | - |
| Return on average assets | -18.37% | -55.31% |
| Return on average equity | -22.96% | - |
| Employees | 25 |
No comments:
Post a Comment